As a result of the great infrastructure facilities suitable for operations and growth, world-class services, and operational facilities provided by DAFZA; multinational companies represent 40% of the total companies operating in the healthcare, pharmaceuticals, health services and equipment industry at DAFZA
DAFZA will also be showcasing two packages; including the Premium, which provides a trade license, two residency visas, and a 25sqm furnished office space; and Premium Plus, which provides a trade license, six residency visas, and a 50sqm furnished office space.
Also at the event, DAFZA will be showcasing the features of its Light Industrial Units provided to these types of companies. The 350sqm insulated units can be used as storage and distribution warehouses, with an office on the ground floor. These options serve the different needs of companies in these sectors; from size, flexibility, cost efficiency, and competitive rates.
DAFZA’s participation will also include showcasing more than 2,000 new business domains which were introduced last July and can be selected for the trade license. The businesses were divided into 18 key categories, in line with the UN’s International Standard Industrial Classification of All Economic Activities (ISIC4), which is the international standard of businesses globally.
This step was taken after a revision by DAFZA of the registration and licensing fees in 2018, and new investors’ visa fees. DAFZA’s registration fees were reduced by 65%, employee visa fees by 20%, certificate of origin fees by 17. These incentives facilitated providing new investors with public trading licenses, by decreasing the capital limit from AED1 million to AED500,000. The companies are also able to be incorporated as “Free Zone – Limited Liability Companies” to allow for a greater flexibility in incorporating, and operating businesses.
Healthcare companies operating within DAFZA include, Johnson & Johnson; Forever Living; Abbott Laboratories; MED-EL Medical Electronics; NSK Middle East; Paul Hartmann Middle East; Vygon Middle East; The Himalaya Drug Co; Hetero; Nipro Middle East; amongst other.